← All organizations
Highest phase reached
Phase 3
First clinical trial
Mar 1, 2000Last known activity
Jan 31, 2026
Timeline
1990s
- Jan 1, 1994
Agenus Inc.— Founded
2000s
- Apr 1, 2001
Aronex Pharmaceuticals— Acquired
2010s
- Feb 13, 2014
4-Antibody AG— Acquired
- Apr 7, 2015
Celexion— Acquired
- Dec 27, 2015
PhosImmune— Acquired
Drugs by trial phase (52 distinct, 68 trials)
Phase 3 (14 own, 4 via acquisition)
Phase 2 (21 own, 1 via acquisition)
Phase 1 (11 own, 1 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Central Nervous System Neoplasms
- Glioblastoma
- Gliosarcoma
- Hemangiosarcoma
- Herpes Genitalis
- Herpes Simplex
- Kidney Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Melanoma
- Neoplasms
- Nervous System Neoplasms
- Recurrence
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Sarcoma
- Syndrome
- Uterine Cervical Neoplasms
Subsidiaries (4 direct, 4 total across the full acquisition tree)
Recent trials (50)
- NCT06751524OfficialN/A—
- NCT05572970Lead sponsorN/A—
- NCT06751524Lead sponsorN/A—
- NCT05572970Study directorN/A—
- NCT07128355CollaboratorEarly Phase 1Jan 31, 2026
- NCT07152821CollaboratorPhase 3Nov 30, 2025
- NCT07227636CollaboratorPhase 2Nov 7, 2025
- NCT06843551CollaboratorPhase 2Jun 1, 2025
- NCT06782932CollaboratorPhase 1/Phase 2May 27, 2025
- NCT06843434CollaboratorPhase 2Feb 20, 2025
- NCT06411691CollaboratorPhase 1Nov 4, 2024
- NCT06346197CollaboratorPhase 3Oct 15, 2024
- NCT06268015CollaboratorPhase 2Oct 1, 2024
- NCT06322108CollaboratorPhase 2May 31, 2024
- NCT06300463CollaboratorPhase 2Mar 26, 2024
Details
- Founded
- Lexington, MA, US Jan 1, 1994
- Last known activity
- Jan 31, 2026